Please login or register first to view this content.
Oncology Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
- Bladder, kidney, and other urologic cancers
- Bone and connective tissue cancer
- Breast cancer
- CNS cancer
- Colorectal and other GI cancers
- Cytoprotective and supportive care agents
- Eye cancer
- Gynecologic cancer
- Head and neck cancer
- Kaposi’s sarcoma
- Leukemias, lymphomas, and other hematologic cancers
- Melanoma and other skin cancers
- Pancreatic, thyroid, and other endocrine cancers
- Prostate and other male cancers
- Respiratory and thoracic cancers
NEWS & FEATURES
Tivdak Approved for Recurrent or Metastatic Cervical Cancer
Durvalumab Plus Chemo Showed Continued Survival Benefit in Extensive-Stage SCLC
Cabometyx Approved for Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Ribociclib Improves Survival by More Than 1 Year in Advanced Breast Cancer
Trastuzumab Deruxtecan: A New Standard for Second-Line Therapy in HER2+ Metastatic Breast Cancer?
Real-Time Mammography Reading Cuts Disparities in Diagnostic Imaging
Brigatinib Continues to Best Crizotinib in ALK+ Non-Small Cell Lung Cancer
Exkivity Approved for EGFR Exon 20 Insertion+ NSCLC
Brukinsa Gets Accelerated Approval for Marginal Zone Lymphoma
Some Cancer Drugs Without Proven Benefit Still Recommended
Tislelizumab Under Review for Esophageal Squamous Cell Carcinoma
Very High Antibiotic Use May Up Risk for Proximal Colon Cancer
MPR Weekly Dose Podcast Episode 92
Which Cancer Patients Need a COVID-19 Booster Shot Most?
Cisplatin-Induced Hearing Loss Up for Young Children With Cancer
Brukinsa Approved for Waldenström Macroglobulinemia
Antihypertensives Linked to Reduced Mortality in Colorectal Cancer
FDA: New Warnings and Limitations Set for Certain JAK Inhibitors
